Squarepoint Ops LLC Takes $2.14 Million Position in ANI Pharmaceuticals, Inc. $ANIP

Squarepoint Ops LLC purchased a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 32,744 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,137,000. Squarepoint Ops LLC owned approximately 0.15% of ANI Pharmaceuticals as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Advisors Asset Management Inc. bought a new stake in ANI Pharmaceuticals in the first quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd lifted its stake in shares of ANI Pharmaceuticals by 4,636.4% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company’s stock valued at $34,000 after purchasing an additional 510 shares during the last quarter. Newbridge Financial Services Group Inc. lifted its stake in shares of ANI Pharmaceuticals by 200.0% in the 2nd quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock valued at $39,000 after purchasing an additional 400 shares during the last quarter. State of Wyoming bought a new stake in ANI Pharmaceuticals in the second quarter worth $50,000. Finally, Emerald Advisers LLC increased its position in ANI Pharmaceuticals by 414.8% during the second quarter. Emerald Advisers LLC now owns 1,256 shares of the specialty pharmaceutical company’s stock worth $82,000 after buying an additional 1,012 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, Director Renee P. Tannenbaum sold 1,800 shares of the firm’s stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $81.15, for a total value of $146,070.00. Following the completion of the sale, the director owned 25,157 shares in the company, valued at approximately $2,041,490.55. This trade represents a 6.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Chad Gassert sold 14,642 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $89.07, for a total value of $1,304,162.94. Following the sale, the senior vice president directly owned 158,584 shares in the company, valued at $14,125,076.88. The trade was a 8.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 26,379 shares of company stock worth $2,313,281 in the last three months. Corporate insiders own 11.10% of the company’s stock.

ANI Pharmaceuticals Stock Up 0.6%

ANIP opened at $82.83 on Friday. The business has a 50 day moving average of $86.84 and a 200-day moving average of $81.20. The stock has a market capitalization of $1.86 billion, a price-to-earnings ratio of 50.82 and a beta of 0.48. The company has a current ratio of 2.58, a quick ratio of 2.04 and a debt-to-equity ratio of 1.20. ANI Pharmaceuticals, Inc. has a 1-year low of $52.50 and a 1-year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.74 by $0.30. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. The firm had revenue of $227.81 million during the quarter, compared to analysts’ expectations of $211.92 million. During the same period in the prior year, the company earned $1.34 EPS. The business’s quarterly revenue was up 53.6% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. As a group, sell-side analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Zacks Research raised ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 21st. HC Wainwright boosted their target price on ANI Pharmaceuticals from $93.00 to $121.00 and gave the stock a “buy” rating in a report on Wednesday, September 17th. Truist Financial increased their price target on ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a report on Thursday, October 9th. JPMorgan Chase & Co. lifted their price target on shares of ANI Pharmaceuticals from $95.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, September 24th. Finally, Barclays assumed coverage on shares of ANI Pharmaceuticals in a report on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $102.14.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.